XBIT XBiotech Inc.

7.82
-0.25  -3%
Previous Close 8.07
Open 8.00
Price To book 3.45
Market Cap 275.97M
Shares 35,290,000
Volume 64,262
Short Ratio 54.89
Av. Daily Volume 177,695

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 16, 2017.
MABp1
Hidradenitis Suppurativa (HS)
Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. BPC estimate is for data release 2Q 2017.
Xilonix
Pyoderma Gangrenosum
Phase 1/2 top-line data released April 3, 2017. 4 patient deaths noted.
514G3
Staphylococcus Aureus Bacteremia
Phase 3 interim analysis announced February 21, 2017 - trial to continue as planned.
Xilonix
Colorectal cancer

Latest News

  1. Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme
  2. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
  3. XBiotech No. 2 Executive Resigns, Leaving Struggling Biotech Without Top Operations Chief
  4. Edited Transcript of XBIT earnings conference call or presentation 4-May-17 12:30pm GMT
  5. Investor Network: XBiotech, Inc. to Host Earnings Call
  6. Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp. and XBIOTECH INC.
  7. XBiotech to Provide First Quarter 2017 Business Update
  8. XBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm
  9. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
  10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
  11. Why XBiotech Inc. Got Crushed Today
  12. XBiotech Stock Crumbles Following Disappointing EMA Meeting
  13. Biotech Movers: XBiotech, Atara, Bellicum
  14. XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection
  15. XBiotech Announces Outcome of EMA's Oral Explanation Meeting
  16. XBiotech Announces Additions To Its Scientific Advisory Board
  17. XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About